Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Stage: Development-stage biopharmaceutical company focused on acquiring and developing small molecule therapeutics.
Key Developments: The company is integrating the Avigen, Inc. acquisition (closed Dec 2009) to combine ibudilast-based programs (MN-166/AV411). Primary focus remains on MN-221 for asthma/COPD and MN-166/AV411 for CNS disorders. The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(5.70) million | $(15.20) million | N/A |
| Operating Expenses | $(4.15) million | $(13.54) million | N/A |
| Cash & Cash Equivalents | N/A | N/A | $31.16 million |
| Total Assets | N/A | N/A | $76.67 million |
| Total Liabilities | N/A | N/A | $47.45 million |
| Stockholders' Equity | N/A | N/A | $29.22 million |
| Accumulated Deficit | N/A | N/A | $(262.55) million |
Debt & Liquidity:
- Long-Term Debt: $15.0 million senior secured loan (Oxford Finance Corp) entered May 2010. Interest rate 12.87% (effective 18.14%). Maturity August 2013.
- Convertible Notes: $28.28 million outstanding (related to Avigen acquisition), maturing June 2011.
- Liquidity: Management believes current cash and equivalents are sufficient to fund operations through at least September 30, 2011.
Material Changes vs. Prior Period
- Net Loss: Increased to $5.70 million for Q3 2010 from $4.80 million in Q3 2009. For the nine months, loss increased to $15.20 million from $14.45 million.
- Operating Expenses: Total operating expenses decreased slightly in Q3 ($4.15M vs $4.94M) and YTD ($13.54M vs $15.15M) due to reduced professional fees and unallocated R&D costs.
- Investment Securities: Recorded a net impairment charge of $0.87 million in Q3 2010 (vs. a gain of $0.07 million in Q3 2009) due to writing down securities to liquidation value. The UBS ARS Put and associated loan were redeemed/repaid in July 2010.
- Interest Expense: Increased significantly to $0.66 million in Q3 2010 (vs. $0.06 million in Q3 2009) due to the new $15M long-term debt, partially offset by the repayment of the ARS loan.
- Balance Sheet: Cash increased from $19.24 million (Dec 31, 2009) to $31.16 million (Sep 30, 2010), driven by the $15M debt financing and redemption of UBS ARS, offset by operating cash burn.
Guidance, Outlook, Risks, and Unusual Items
Outlook & Guidance:
- Management expects to continue incurring significant operating losses.
- Anticipates R&D expenses will increase for MN-221 over the next two quarters to complete the ongoing Phase II clinical trial (MN-221-CL-007).
- Plans to limit expenditures on non-prioritized assets to maintain license rights while seeking strategic partners.
- Believes current capital is sufficient through September 30, 2011, but will require additional funding for future operations.
Material Weakness in Internal Controls:
- Management identified a material weakness in internal control over financial reporting as of September 30, 2010.
- Cause: Control overrides and policy deviations by a senior executive officer regarding Code of Conduct, contract review, and HR policies.
- Remediation: Board revised policies (dual signatures for contracts, Compensation Committee oversight) and changed reporting lines. Remediation was ongoing as of the filing date.
Risks & Contingencies:
- Debt Covenants: The $15M loan requires either a $15M collaboration deal or positive Phase IIB data on MN-221 by March 31, 2011. Failure triggers immediate repayment and higher interest rates.
- Clinical Trials: MN-221 trial enrollment has been slower than expected, though improved in Q3 2010 due to protocol amendments.
- Legal: Settled a shareholder lawsuit regarding the Avigen transaction for $140,000 (paid by insurance) in July 2010.
Investor Verification Checklist
- Debt Covenant Compliance: Verify progress toward the March 31, 2011 milestone (partnership or Phase IIB data) required to avoid default on the $15M Oxford Finance loan.
- Cash Burn Rate: Confirm if the $31.2 million cash balance is sufficient to fund the MN-221 trial completion and operations through the projected September 2011 runway.
- Internal Control Remediation: Monitor the effectiveness of the new controls implemented to address the material weakness identified in Q3 2010.
- Clinical Enrollment: Track patient enrollment rates for the MN-221-CL-007 trial to assess the risk of delays and associated cost overruns.
- Convertible Notes: Review the conversion activity of the $28.3 million Avigen-related notes maturing in June 2011 and the potential dilution or cash outflow implications.